795 results
SGLT2 Inhibitors and Cardiovascular Pathophysiology

#SGLT2i #Inhibitors #Cardiovascular #Pathophysiology
SGLT2 Inhibitors ... Cardiovascular Pathophysiology ... #SGLT2i #Inhibitors ... Cardiovascular #Pathophysiology
Pathophysiology Euglycemic DKA - Mechanism of SGLT-2 Inhibitors #Pathophys #Endocrine #Euglycemic #DKA #SGLT2 #Mechanism
Pathophysiology ... - Mechanism of SGLT ... Euglycemic #DKA #SGLT2
Pathophysiology of Euglycemic DKA in SGLT2 Inhibitors
 • Kidney: Glycosuria, Natriuresis, ↑ Ketone bodies reabsorption
 •
Pathophysiology ... Euglycemic DKA in SGLT2 ... Euglycemic #DKA #SGLT2i ... #Inhibitors #pathophysiology
How SGLT2 inhibitors block glucose reabsorption in proximal tubule and improve systemic glucose homeostasis:
https://www.ajkd.org/article/S0272-6386(18)30633-4/fulltext

#Pathophysiology #Mechanism #Nephrology
How SGLT2 inhibitors ... -4/fulltext #Pathophysiology ... Mechanism #Nephrology #SLGT2
Mechanism of Action for Common Diabetes Medications

 • SGLT2i (Dapagliflozin)
 • TZD (Pioglitazone)
 • Biguanides (Metformin)
Medications • SGLT2i ... #pharmacology #pathophysiology
Euglycemic Diabetic Ketoacidosis (EuDKA)
SGLT2 Inhibitors
Increasing Indications
Significant Adverse Drug Effects
Definition of EuDKA
 • Metabolic acidosis with pH
Ketoacidosis (EuDKA) SGLT2 ... level < 200 mg/dL Pathophysiology
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
Clinical Trials of SGLT2 ... ASCVD; signal for SGLT2i ... risk; signal for SGLT2i ... outcomes trial in SGLT2i ... mcclaffertyMD #SGLT2
Cardiovascular and renal effects comparison between SGLT-2 inhibitors
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Empagliflozin
comparison between SGLT ... cardiovascular #renal #SGLT2i
SGLT2 Inhibitors and Euglycemic DKA

Risk factors for euglycemic DKA in those on an SGLT2i include:
 •
SGLT2 Inhibitors ... in those on an SGLT2i ... is closed • SGLT2 ... Kat_Watson #SGLT2
#SGLT2i #patientinfo #nephrology
#SGLT2i #patientinfo